Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

From the Wells Fargo presentaion:


* Glatopa scripts represent 38% of the 20 mg glatiramer acetate
market in the U.S.

• Estimated annual cost savings in 2016 for Glatopa 20 mg
versus the daily COPAXONE 20 mg dose is ~$17k per patient
based on US wholesale acquisition costs

If the price savings is truly $17K per patient annually, I'm surprised they only have 38% of the available market.